AI assistant
Tarsus Pharmaceuticals, Inc. — Director's Dealing 2022
Aug 19, 2022
31511_dirs_2022-08-19_e6b66165-dd74-44e5-bea7-ff01cd57262a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Tarsus Pharmaceuticals, Inc. (TARS)
CIK: 0001819790
Period of Report: 2022-08-18
Reporting Person: Greenstein Leonard M. (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-08-18 | Common Stock | S | 5000 | $16.30 | Disposed | 64289 | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022.
F2: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $15.99 to $16.71. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Includes 862 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021, and 1,111 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022.